Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Receivables (2022 - 2025)

Arcutis Biotherapeutics has reported Receivables over the past 4 years, most recently at $146.2 million for Q4 2025.

  • Quarterly results put Receivables at $146.2 million for Q4 2025, up 100.13% from a year ago — trailing twelve months through Dec 2025 was $146.2 million (up 100.13% YoY), and the annual figure for FY2025 was $146.2 million, up 100.13%.
  • Receivables for Q4 2025 was $146.2 million at Arcutis Biotherapeutics, up from $115.1 million in the prior quarter.
  • Over the last five years, Receivables for ARQT hit a ceiling of $146.2 million in Q4 2025 and a floor of $2.4 million in Q3 2022.
  • Median Receivables over the past 4 years was $40.3 million (2024), compared with a mean of $53.8 million.
  • Biggest five-year swings in Receivables: soared 698.72% in 2023 and later surged 91.48% in 2025.
  • Arcutis Biotherapeutics' Receivables stood at $8.5 million in 2022, then skyrocketed by 205.12% to $25.8 million in 2023, then surged by 183.12% to $73.1 million in 2024, then soared by 100.13% to $146.2 million in 2025.
  • The last three reported values for Receivables were $146.2 million (Q4 2025), $115.1 million (Q3 2025), and $106.7 million (Q2 2025) per Business Quant data.